Paklitaxel albumin Reddy: Uses, Dosage & Side Effects
Generic albumin-bound paclitaxel nanoparticle (nab-paclitaxel) 5 mg/ml powder for infusion, used in the treatment of metastatic breast cancer, pancreatic adenocarcinoma and non-small cell lung cancer
Paklitaxel albumin Reddy is a generic formulation of albumin-bound paclitaxel nanoparticles (nab-paclitaxel), manufactured by Dr. Reddy's Laboratories and supplied as a white to yellowish lyophilized powder that is reconstituted to a milky suspension of 5 mg/ml before intravenous infusion. It contains the same active ingredient as the originator product Abraxane: paclitaxel bound to human serum albumin as nanoparticles approximately 130 nanometers in diameter. Paclitaxel is a taxane cytotoxic chemotherapy agent that works by stabilizing the microtubule network inside cells, preventing normal cell division and triggering programmed cell death (apoptosis). The albumin-bound formulation eliminates the need for the toxic solvent Cremophor EL used in conventional paclitaxel, allowing shorter 30-minute infusions without routine corticosteroid and antihistamine premedication. Paklitaxel albumin Reddy is authorized for metastatic breast cancer (monotherapy), metastatic pancreatic adenocarcinoma (with gemcitabine), and locally advanced or metastatic non-small cell lung cancer (with carboplatin). It is a prescription-only hospital-administered medicine.
Quick Facts: Paklitaxel albumin Reddy
Key Takeaways
- Paklitaxel albumin Reddy is a generic albumin-bound paclitaxel (nab-paclitaxel) 5 mg/ml powder for infusion, pharmacologically equivalent to the reference product Abraxane, manufactured by Dr. Reddy's Laboratories.
- It is authorized for three cancer types: metastatic breast cancer (after failure of first-line therapy), metastatic pancreatic adenocarcinoma (with gemcitabine), and non-small cell lung cancer (with carboplatin) when surgery or radiation are not suitable.
- The most common side effects include hair loss, peripheral neuropathy (numbness and tingling), low blood cell counts, nausea, fatigue, and muscle pain; dose reductions and treatment delays are used to manage these effects.
- Paklitaxel albumin Reddy must not be used if the neutrophil count is below 1,500/mm³, during breastfeeding, or in patients with known hypersensitivity to paclitaxel; effective contraception is required for both women and men.
- Because it is solvent-free (no Cremophor EL), Paklitaxel albumin Reddy is infused over 30 minutes without routine corticosteroid or antihistamine premedication, unlike conventional paclitaxel formulations.
What Is Paklitaxel albumin Reddy and What Is It Used For?
The active substance in Paklitaxel albumin Reddy is paclitaxel, one of the most widely used and clinically validated chemotherapy agents in oncology. Paclitaxel belongs to the taxane family of antineoplastic drugs, a class that also includes docetaxel and cabazitaxel. Taxanes exert their anticancer activity by binding to the beta-tubulin subunits of microtubules and stabilizing the resulting polymer, preventing its normal depolymerization. Microtubules are dynamic cellular structures essential for mitotic spindle formation, intracellular transport, and cell signaling. When paclitaxel stabilizes these structures, cancer cells become arrested at the G2/M phase of the cell cycle, are unable to complete mitosis, and ultimately undergo programmed cell death (apoptosis).
What distinguishes Paklitaxel albumin Reddy from conventional paclitaxel formulations is its nanoparticle delivery system. Conventional solvent-based paclitaxel requires Cremophor EL (polyoxyethylated castor oil) to dissolve the drug, because paclitaxel itself is almost insoluble in water. Cremophor EL is associated with severe hypersensitivity reactions, including anaphylaxis, and necessitates extensive premedication with corticosteroids, antihistamines, and H2-receptor antagonists, as well as prolonged 3-hour infusion times. In Paklitaxel albumin Reddy, paclitaxel is bound to human serum albumin as nanoparticles approximately 130 nanometers in diameter. This albumin-bound nanoparticle formulation (nab technology) allows the drug to be suspended in physiological saline without any toxic solvents.
The albumin carrier serves a dual purpose. First, it provides a solvent-free delivery vehicle that eliminates Cremophor-related toxicity and the need for routine premedication, enabling shorter 30-minute infusions. Second, published research suggests that albumin facilitates transport of paclitaxel across the endothelial cell barrier of blood vessels and into tumor tissue through a receptor-mediated process involving the glycoprotein receptor gp60 and the albumin-binding protein SPARC (secreted protein, acidic and rich in cysteine), which is overexpressed in many solid tumors. This biology may contribute to higher intratumoral drug concentrations compared with solvent-based paclitaxel, potentially improving anticancer efficacy.
As a generic medicine, Paklitaxel albumin Reddy has been developed to be pharmaceutically and therapeutically equivalent to the reference nab-paclitaxel product. Generic oncology medicines such as Paklitaxel albumin Reddy improve global access to modern chemotherapy by reducing treatment costs while delivering the same clinical efficacy and safety profile as the originator product. The following indications are authorized for nab-paclitaxel products and apply to Paklitaxel albumin Reddy in jurisdictions where it holds marketing authorization:
Metastatic Breast Cancer
Paklitaxel albumin Reddy is indicated as monotherapy for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard anthracycline-containing therapy is not indicated. The pivotal phase III trial (Gradishar et al., Journal of Clinical Oncology, 2005) compared nab-paclitaxel 260 mg/m² every 3 weeks with conventional paclitaxel 175 mg/m² every 3 weeks in 460 women with metastatic breast cancer. Patients receiving nab-paclitaxel had significantly higher overall response rates (33% vs. 19%, p=0.001) and longer time to tumor progression (23.0 vs. 16.9 weeks, p=0.006). Despite the higher delivered paclitaxel dose, the incidence of grade 4 neutropenia was lower with the albumin-bound formulation, and severe hypersensitivity reactions were virtually eliminated even without routine premedication.
Metastatic Pancreatic Cancer
Paklitaxel albumin Reddy is indicated in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. The landmark MPACT trial (Von Hoff et al., New England Journal of Medicine, 2013) randomized 861 patients with previously untreated metastatic pancreatic cancer to receive either nab-paclitaxel plus gemcitabine or gemcitabine alone. The combination arm demonstrated a statistically significant improvement in overall survival (median 8.5 vs. 6.7 months, hazard ratio 0.72, p<0.001), progression-free survival (5.5 vs. 3.7 months, p<0.001), and overall response rate (23% vs. 7%, p<0.001). This trial established nab-paclitaxel plus gemcitabine as a standard of care for metastatic pancreatic cancer, a disease that had previously seen limited advances in first-line therapy for decades.
Non-Small Cell Lung Cancer
Paklitaxel albumin Reddy is indicated in combination with carboplatin for the first-line treatment of non-small cell lung cancer (NSCLC) in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. A phase III trial (Socinski et al., Journal of Clinical Oncology, 2012) randomized 1,052 patients with previously untreated stage IIIB/IV NSCLC to receive either nab-paclitaxel 100 mg/m² weekly (3 weeks on, 1 week off) plus carboplatin AUC 6 every 3 weeks, or conventional paclitaxel 200 mg/m² plus carboplatin AUC 6 every 3 weeks. The nab-paclitaxel regimen achieved a significantly higher overall response rate (33% vs. 25%, p=0.005), with a favorable toxicity profile including reduced neuropathy, neutropenia, arthralgia, and myalgia compared with the solvent-based comparator.
The nab platform represents a significant advance in cytotoxic drug delivery. By harnessing the natural properties of human albumin – the most abundant protein in human blood plasma – nab-paclitaxel achieves solvent-free drug delivery, shorter infusion times (30 minutes vs. 3+ hours), elimination of routine corticosteroid and antihistamine premedication, and potential for enhanced tumor uptake through albumin-mediated active transport (gp60 / SPARC pathway). Paklitaxel albumin Reddy utilizes this technology while providing broader patient access through generic availability.
What Should You Know Before Receiving Paklitaxel albumin Reddy?
Contraindications
There are specific clinical situations in which Paklitaxel albumin Reddy must not be administered. Understanding these contraindications is essential to prevent serious adverse outcomes. Your oncologist will screen for these conditions before prescribing the medicine.
- Hypersensitivity: Do not receive Paklitaxel albumin Reddy if you have a known allergy (hypersensitivity) to paclitaxel or to any of the excipients in the formulation, including human albumin. Even though nab-paclitaxel is far less likely to cause hypersensitivity than solvent-based paclitaxel, severe reactions can still occur in rare cases.
- Breastfeeding: Paklitaxel albumin Reddy must not be used during breastfeeding. It is not known whether paclitaxel passes into human breast milk, and the potential risk to a nursing infant is considered unacceptable.
- Severe neutropenia at baseline: Treatment must not be started or continued if the baseline neutrophil count is below 1,500 cells/mm³ (1.5 × 10&sup9;/L). Your doctor will check your complete blood count before each treatment cycle.
Warnings and Precautions
Paklitaxel albumin Reddy can cause severe suppression of bone marrow function, leading to dangerously low levels of white blood cells (neutropenia), red blood cells (anemia), and platelets (thrombocytopenia). This increases the risk of serious infection and bleeding. Your oncology team will monitor your blood counts regularly and may delay treatment or reduce your dose if counts are too low. Contact your medical team immediately if you develop fever above 38°C (100.4°F), sore throat, unusual bruising, persistent bleeding, or any signs of infection.
Tell your doctor or nurse before receiving Paklitaxel albumin Reddy if any of the following apply to you:
- Kidney problems: If you have impaired kidney function, your medical team should be informed. While paclitaxel is primarily metabolized by the liver, kidney impairment may affect overall drug clearance and toxicity profiles, and dose adjustments may be appropriate.
- Liver problems: Paclitaxel is extensively metabolized by the liver via the cytochrome P450 enzymes CYP2C8 and CYP3A4. Patients with moderate or severe hepatic impairment (elevated bilirubin or aminotransferases) are at increased risk of toxicity, and dose reductions are typically required. Your doctor will perform liver function tests before and during treatment and will withhold therapy when hepatic parameters are outside acceptable ranges.
- Heart problems: Cases of cardiac conduction abnormalities, including atrioventricular block and bradycardia, have been reported with paclitaxel. Rarely, heart failure and myocardial infarction have occurred. Inform your doctor if you have any pre-existing heart conditions, a history of arrhythmia, or if you are taking medications that affect heart rhythm.
- Pre-existing peripheral neuropathy: If you already have numbness, tingling, or pain in your hands or feet from a previous chemotherapy regimen (such as prior taxane or platinum therapy), diabetes, or any other cause, tell your doctor. Pre-existing neuropathy may worsen with treatment, and the starting dose or schedule may need adjustment.
- Active infection: Active or uncontrolled infections should be treated before starting Paklitaxel albumin Reddy because myelosuppression may worsen the clinical course.
During treatment with Paklitaxel albumin Reddy, contact your medical team immediately if you experience any of the following:
- Unusual bruising, bleeding that does not stop, or any signs of infection (fever, chills, sore throat, painful urination)
- New or worsening numbness, tingling, prickling, sensitivity to touch, or muscle weakness, especially in the hands and feet
- Breathing problems such as shortness of breath, dry cough, or wheezing that could indicate lung inflammation or pulmonary embolism
- Severe abdominal pain, persistent nausea or vomiting, or inability to keep fluids down
- Severe skin reactions such as widespread rash, blistering, skin peeling, or mucous membrane involvement (mouth or eye ulcers)
- Chest pain, palpitations, fainting, or a sudden slow or fast heart rate
Pregnancy and Breastfeeding
Paclitaxel has been shown to cause serious birth defects and embryofetal harm in animal reproductive toxicity studies. Paklitaxel albumin Reddy should not be used during pregnancy. Your doctor will arrange a pregnancy test before starting treatment in women of childbearing potential to confirm that you are not pregnant.
Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose of Paklitaxel albumin Reddy. Inform your doctor immediately if you become pregnant or suspect you may be pregnant during or shortly after treatment.
Breastfeeding is contraindicated during treatment and for a period after the last dose, as it is unknown whether paclitaxel is excreted in human breast milk and the potential risk to the nursing infant is considered too significant to allow breastfeeding.
Male patients should use effective contraception and avoid fathering children during treatment and for at least 3 months after the last dose. Men of reproductive age are advised to seek counseling about sperm cryopreservation (freezing) before starting treatment, as cytotoxic chemotherapy can cause reduced fertility that may be permanent. Referral to a fertility specialist before the first cycle is appropriate for many patients.
Children and Adolescents
Paklitaxel albumin Reddy is indicated for adult patients only. It should not be administered to children or adolescents under 18 years of age. Safety and efficacy in the pediatric population have not been established, and no pediatric cancer indications are currently approved for nab-paclitaxel products in major jurisdictions.
Elderly Patients
Paklitaxel albumin Reddy may be used in elderly patients, but older adults may be at increased risk for certain adverse events, including myelosuppression, fatigue, and dehydration. Your oncologist will assess your overall performance status, comorbidities, organ function, and nutritional status before recommending the treatment schedule. Closer clinical monitoring and supportive care (hydration, nutritional counseling, and prompt management of side effects) are typically recommended in elderly patients.
Driving and Operating Machinery
Some patients may experience tiredness, dizziness, or blurred vision during or after treatment with Paklitaxel albumin Reddy. If you experience any of these symptoms, do not drive, use tools, or operate machinery until they have fully resolved. On days when you receive an infusion, it is generally advisable to arrange transportation home and to avoid demanding physical or cognitive tasks for the remainder of the day.
Important Information About Ingredients
Paklitaxel albumin Reddy contains human albumin solution as the only significant excipient. No Cremophor EL, ethanol, or other potentially problematic solvents are present. Each 100 mg vial contains less than 1 mmol (23 mg) of sodium, which means it is essentially sodium-free; this is relevant for patients on sodium-restricted diets. Because the formulation contains a blood product (human serum albumin), theoretical risks of transmission of infectious agents are addressed through strict donor selection, individual donation testing, and viral inactivation and removal steps during manufacturing. No cases of viral transmission have been linked to licensed human albumin preparations.
How Does Paklitaxel albumin Reddy Interact with Other Drugs?
Paclitaxel is metabolized primarily by the hepatic cytochrome P450 enzymes CYP2C8 (approximately 60% of metabolism) and CYP3A4 (approximately 30% of metabolism). Any medication that significantly inhibits or induces these enzymes can alter the plasma concentrations of paclitaxel, potentially leading to increased toxicity or reduced therapeutic effectiveness. It is essential to give your oncologist a complete and current list of every medicine, vitamin, dietary supplement, and herbal product you are taking or have recently taken, including over-the-counter products.
Caution is also warranted when Paklitaxel albumin Reddy is administered together with other drugs that have overlapping toxicity profiles, particularly those affecting the bone marrow (other cytotoxic agents), the nervous system (drugs causing peripheral neuropathy), or the liver (hepatotoxic agents). When used in combination with gemcitabine or carboplatin according to approved regimens, the interaction profiles of these partner drugs must also be considered.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Ketoconazole, itraconazole, voriconazole (strong CYP3A4 inhibitors) | Increased paclitaxel plasma levels; greater risk of myelosuppression and neuropathy | Avoid combination; if unavoidable, monitor blood counts closely and consider dose reduction |
| Rifampicin, rifabutin (strong CYP3A4/CYP2C8 inducers) | Decreased paclitaxel plasma levels; potentially reduced anticancer efficacy | Avoid combination where possible; therapeutic effectiveness may be diminished |
| Gemfibrozil (strong CYP2C8 inhibitor) | Substantial increase in paclitaxel exposure via CYP2C8 inhibition | Avoid concomitant use; increased risk of severe neutropenia and peripheral neuropathy |
| Clopidogrel (CYP2C8 inhibitor) | May inhibit CYP2C8-mediated paclitaxel metabolism, increasing paclitaxel levels | Use with caution; monitor for increased side effects and cytopenias |
| Live attenuated vaccines (e.g., measles, mumps, rubella, yellow fever, varicella) | Risk of severe or fatal disseminated vaccine-strain infection in immunocompromised patients | Do not administer during and generally for at least 3 months after chemotherapy; check with specialist |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Erythromycin, clarithromycin (moderate CYP3A4 inhibitors) | Possible modest increase in paclitaxel plasma levels | Monitor for increased side effects; dose adjustment may be needed |
| Fluoxetine (antidepressant / CYP2C8 inhibitor) | May modestly increase paclitaxel exposure | Use with caution; monitor for bone marrow suppression and neuropathy |
| Carbamazepine, phenytoin, phenobarbital (CYP3A4 inducers) | May decrease paclitaxel plasma levels | Potential for reduced efficacy; consider alternative anticonvulsants if possible |
| St. John's wort (Hypericum perforatum) | Potent inducer of CYP3A4; may reduce paclitaxel levels and efficacy | Avoid during chemotherapy; counsel patients about herbal products |
| Cimetidine (H2-receptor antagonist) | Weak CYP3A4 inhibitor; minor effect on paclitaxel metabolism | Generally safe; clinical significance is low |
| HIV antiretrovirals (e.g., ritonavir, efavirenz, nevirapine) | Variable effects on CYP3A4 (ritonavir is a potent inhibitor; efavirenz and nevirapine are inducers) | Requires careful evaluation; consult with both oncologist and HIV specialist |
| Anticoagulants (warfarin, direct oral anticoagulants) | Paclitaxel-induced thrombocytopenia may increase bleeding risk | Monitor platelets and coagulation; consider dose adjustment of anticoagulant |
When Paklitaxel albumin Reddy is used in combination regimens (with gemcitabine for pancreatic cancer or with carboplatin for lung cancer), the interaction profiles of the partner drugs must also be considered. Gemcitabine is primarily cleared renally and has few CYP-mediated interactions, while carboplatin interacts minimally with CYP enzymes but has significant renal clearance and dose-limiting thrombocytopenia. Your oncologist will carefully plan and monitor your combined therapy to minimize cumulative and overlapping toxicities.
What Is the Correct Dosage of Paklitaxel albumin Reddy?
Paklitaxel albumin Reddy is always administered by a doctor or a specialist oncology nurse as an intravenous infusion over 30 minutes. The dose is calculated individually for each patient based on body surface area (BSA), which is determined from your height and weight using a standard formula such as the Mosteller equation. Your doctor will also take into account your blood test results, liver function tests, kidney function, age, performance status, and overall general health when determining the appropriate starting dose and treatment schedule.
Adults – Metastatic Breast Cancer
Paklitaxel albumin Reddy Monotherapy for Metastatic Breast Cancer
Dose: 260 mg/m² body surface area, given as an intravenous infusion over 30 minutes
Schedule: Once every 3 weeks (on Day 1 of each 21-day cycle)
Duration: Treatment continues until disease progression, unacceptable toxicity, or at the discretion of the treating physician
Routine premedication with corticosteroids or antihistamines is not required. Premedication may be considered only if a patient has previously experienced a hypersensitivity reaction during nab-paclitaxel therapy.
Adults – Metastatic Pancreatic Cancer
Paklitaxel albumin Reddy + Gemcitabine for Metastatic Pancreatic Cancer
Dose: 125 mg/m² body surface area, given as an intravenous infusion over 30 minutes
Schedule: On Days 1, 8, and 15 of each 28-day cycle
Partner drug: Gemcitabine 1,000 mg/m² is administered immediately after Paklitaxel albumin Reddy on the same treatment days
Duration: Treatment continues until disease progression, unacceptable toxicity, or loss of clinical benefit
Adults – Non-Small Cell Lung Cancer
Paklitaxel albumin Reddy + Carboplatin for NSCLC
Dose: 100 mg/m² body surface area, given as an intravenous infusion over 30 minutes
Schedule: On Days 1, 8, and 15 of each 21-day cycle
Partner drug: Carboplatin AUC 6 mg·min/ml is administered immediately after Paklitaxel albumin Reddy on Day 1 only of each 21-day cycle
Duration: Treatment continues until disease progression or unacceptable toxicity
| Patient Group / Indication | Dose | Schedule | Route |
|---|---|---|---|
| Adults – metastatic breast cancer | 260 mg/m² | Day 1, every 21 days | 30-min IV infusion |
| Adults – metastatic pancreatic cancer (+ gemcitabine) | 125 mg/m² | Days 1, 8, 15 of 28-day cycle | 30-min IV infusion |
| Adults – non-small cell lung cancer (+ carboplatin) | 100 mg/m² | Days 1, 8, 15 of 21-day cycle | 30-min IV infusion |
| Children & adolescents (<18 years) | Not indicated | Not recommended | – |
| Elderly (≥65 years) | Same as adults | Consider closer monitoring and supportive care | 30-min IV infusion |
| Hepatic impairment (mild) | No adjustment typically required | Monitor liver function tests | 30-min IV infusion |
| Hepatic impairment (moderate) | Reduce to approx. 200 mg/m² (breast), 80 mg/m² (pancreas), 80 mg/m² (NSCLC) | As per indication | 30-min IV infusion |
| Hepatic impairment (severe) | Generally contraindicated | Do not administer | – |
Dose Adjustments
Your doctor may need to delay treatment, reduce the dose, or discontinue Paklitaxel albumin Reddy based on certain clinical findings during treatment. Dose adjustments are commonly required for the following reasons:
- Neutropenia: If your neutrophil count falls below acceptable levels (typically <1,500/mm³ at the start of a cycle), treatment will be delayed until counts recover. Subsequent doses may be reduced by approximately 20% in case of grade 4 neutropenia lasting ≥7 days or febrile neutropenia.
- Peripheral neuropathy: If you develop grade 3 sensory neuropathy (significant functional impairment with activities of daily living), treatment is withheld until improvement to grade 1 or baseline, and then resumed at a reduced dose (typically one dose level lower).
- Hepatic impairment: Patients with elevated bilirubin (>1.25 × upper limit of normal, ULN) or significantly elevated aminotransferases (AST >10 × ULN) require dose reduction. Severe hepatic impairment (bilirubin >5 × ULN) generally contraindicates use.
- Thrombocytopenia: If platelet counts drop below 100,000/mm³ (or below treatment threshold), dosing may be delayed to reduce bleeding risk.
- Grade 3 or 4 cutaneous or mucosal toxicity: May require dose reduction or discontinuation depending on severity and response to supportive care.
Children
Paklitaxel albumin Reddy is intended for adult patients only. The safety and efficacy of nab-paclitaxel in children and adolescents below 18 years of age have not been established. It is not recommended for use in the pediatric population outside of dedicated clinical trials.
Missed Dose
Because Paklitaxel albumin Reddy is administered only in a clinical setting by healthcare professionals, the risk of a patient-initiated missed dose is minimal. If a scheduled treatment session is missed or delayed due to side effects, intercurrent illness, or scheduling issues, your oncology team will advise you on when to resume treatment. Do not attempt to “make up” a missed dose by receiving a double dose or by scheduling two sessions close together unless specifically instructed by your oncologist.
Overdose
There is no specific antidote for paclitaxel overdose. In the event of accidental overdose, the primary expected complications are severe bone marrow suppression (prolonged and profound neutropenia and thrombocytopenia), peripheral neuropathy, and mucositis (inflammation of the oral and gastrointestinal mucous membranes). Treatment is supportive and symptomatic, and may include granulocyte colony-stimulating factors (G-CSF) for neutropenia, platelet transfusions for bleeding, antibiotic prophylaxis or treatment for infection, and pain management for mucositis. Because Paklitaxel albumin Reddy is administered by trained healthcare professionals in a controlled setting with verified dose calculations, the risk of accidental overdose is very low.
How Paklitaxel albumin Reddy Is Prepared and Given
Paklitaxel albumin Reddy is supplied as a white to yellowish lyophilized powder in glass vials containing 100 mg of paclitaxel. Before administration, the powder is reconstituted with 20 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, which is slowly injected into the vial over at least 1 minute. The solution is directed against the inner wall of the vial to avoid foaming of the albumin. After the vial has stood for at least 5 minutes to ensure proper wetting of the lyophilized cake, it is gently swirled and/or inverted for at least 2 minutes until the powder is completely dissolved, producing a milky, homogeneous suspension at a final concentration of 5 mg/ml.
The calculated patient-specific dose is then aseptically withdrawn from the reconstituted vial and injected into an empty sterile PVC or non-PVC intravenous infusion bag. The infusion is administered through an IV line fitted with an in-line filter of 15 μm pore size to prevent the passage of any proteinaceous strands that may form. The infusion is delivered over 30 minutes. Special DEHP-free containers or administration sets are not required.
Paklitaxel albumin Reddy is a cytotoxic chemotherapy agent that must always be prepared and administered by trained healthcare professionals in a hospital or specialized oncology clinic. Strict safety precautions are required during handling, including the use of gloves, protective eyewear, sealed preparation environments (e.g., biological safety cabinets), and protective clothing. Pregnant healthcare workers should not handle this medication. You will never self-administer this medicine at home.
What Are the Side Effects of Paklitaxel albumin Reddy?
Like all chemotherapy drugs, Paklitaxel albumin Reddy can cause side effects, although not every patient will experience them. The type, frequency, and severity of side effects depend on the dose, treatment schedule, whether it is given alone or in combination with other cytotoxic agents, and individual patient factors such as age, performance status, and comorbidities. Your oncology team will monitor you closely between cycles and take steps to manage side effects as they arise, including dose adjustments, treatment delays, supportive medications (anti-emetics, growth factor support, analgesics), and early intervention for infections.
The side effects listed below are organized by frequency category, based on pooled data from registrational clinical trials with nab-paclitaxel across its approved indications. The categories reflect how commonly each side effect was observed in controlled clinical studies.
Very Common
May affect more than 1 in 10 people
- Hair loss (alopecia) – typically pronounced (>50%), occurring within the first month of treatment
- Skin rash
- Low white blood cell counts (neutropenia, lymphopenia, leukopenia)
- Anemia (low red blood cell count)
- Low platelet count (thrombocytopenia)
- Peripheral neuropathy (numbness, tingling, burning, pain, or loss of sensation in hands and feet)
- Joint pain (arthralgia) and muscle pain (myalgia)
- Nausea, vomiting, diarrhea, constipation, mouth sores (stomatitis), loss of appetite
- Weakness and fatigue, fever
- Dehydration, taste changes, weight loss
- Low potassium levels (hypokalemia)
- Depression, insomnia
- Headache, dizziness
- Shortness of breath (dyspnea)
- Swelling of mucous membranes
- Elevated liver function tests (ALT, AST, alkaline phosphatase)
- Pain in arms and legs, cough, abdominal pain, nosebleeds (epistaxis)
- Chills
Common
May affect up to 1 in 10 people
- Itching (pruritus), dry skin, nail disorders
- Infections (including febrile neutropenia, oral candidiasis/thrush, serious bloodstream infections/sepsis)
- Decreased counts of all blood cell types (pancytopenia)
- Chest or throat pain
- Indigestion, abdominal discomfort
- Nasal congestion
- Back pain, bone pain
- Impaired muscle coordination, visual changes, eyelash loss
- Changes in heart rate or rhythm, heart failure
- Low or high blood pressure
- Redness or swelling at the infusion site
- Anxiety
- Lung infection (pneumonia), urinary tract infection
- Bowel obstruction, inflammation of the colon (colitis) or bile ducts (cholangitis)
- Acute kidney failure
- Elevated bilirubin, coughing up blood (hemoptysis)
- Dry mouth, difficulty swallowing, muscle weakness, blurred vision
Uncommon
May affect up to 1 in 100 people
- Weight gain, increased lactate dehydrogenase (LDH), decreased kidney function, elevated blood sugar, elevated phosphorus
- Decreased reflexes, involuntary movements, nerve pain, fainting, dizziness on standing, tremor, facial paralysis
- Eye irritation, painful or red eyes, itchy eyes, double vision, decreased vision, flashing lights, blurred vision from retinal swelling (cystoid macular edema)
- Ear pain, tinnitus (ringing in ears)
- Productive cough, shortness of breath on exertion, runny or dry nose, decreased breath sounds, fluid on the lungs (pleural effusion), loss of voice, blood clot in the lung (pulmonary embolism), dry throat
- Flatulence, stomach cramps, painful gums, rectal bleeding
- Painful urination, frequent urination, blood in urine, urinary incontinence
- Nail pain, nail loss, hives, skin pain, photosensitivity, skin discoloration, excessive sweating, night sweats, white patches on skin, sores, facial swelling
- Low phosphorus, fluid retention, low albumin, increased thirst, low calcium, low blood sugar, low sodium
- Skin infections, catheter-related infections, bruising
- Tumor site pain, low blood pressure on standing (orthostatic hypotension), cold hands and feet
- Difficulty walking, general swelling (edema), allergic reaction
- Decreased liver function, enlarged liver, chest pain, restlessness
- Small skin hemorrhages from blood clotting abnormalities (petechiae)
- Hemolytic uremic syndrome (breakdown of red blood cells with acute kidney failure)
Rare
May affect up to 1 in 1,000 people
- Skin reaction or lung inflammation following radiation therapy (radiation recall phenomenon)
- Blood clots (deep vein thrombosis)
- Very slow heart rate (bradycardia), heart attack (myocardial infarction)
- Extravasation (leakage of drug from the vein into surrounding tissue, which can cause local injury)
- Irregular conduction of electrical impulses in the heart (atrioventricular block)
Very Rare
May affect up to 1 in 10,000 people
- Stevens-Johnson syndrome (severe skin and mucous membrane inflammation with blistering and peeling)
- Toxic epidermal necrolysis (life-threatening widespread skin detachment)
Not Known
Frequency cannot be estimated from available data
- Scleroderma-like skin changes (hardening and thickening of the skin)
It is important to report any suspected side effects to your healthcare provider. Reporting helps regulatory authorities continuously monitor the benefit-risk balance of medicines. You can also report side effects directly to your national pharmacovigilance agency, such as the FDA MedWatch program in the United States, the Yellow Card scheme in the United Kingdom, the EudraVigilance system in the European Union, or your country's local equivalent. Your reports help make medicines safer for future patients.
How Should Paklitaxel albumin Reddy Be Stored?
Proper storage of Paklitaxel albumin Reddy is essential to maintain its chemical stability, microbiological safety, and therapeutic efficacy. As a hospital-administered medicine, storage is ordinarily managed by hospital pharmacy and oncology nursing staff according to local SOPs, but patients and caregivers may find it useful to understand the basic storage requirements and the reasoning behind them.
- Unopened vials: Store in the original outer carton to protect from light. Paklitaxel albumin Reddy does not require refrigeration or freezing when unopened. Neither freezing nor refrigeration adversely affects product stability. Do not use after the expiry date printed on the carton and vial.
- After reconstitution (in the vial): The reconstituted suspension should ideally be used immediately. If not used immediately, it may be stored in a refrigerator (2–8°C) for up to 24 hours in the original vial within the outer carton to protect from light. Do not freeze the reconstituted suspension.
- After preparation (in the infusion bag): The prepared infusion may be stored refrigerated (2–8°C) for up to 24 hours, protected from light.
- Total combined storage: The total time from reconstitution in the vial, through storage in the infusion bag, and ending with administration, is a maximum of 24 hours refrigerated and protected from light, followed by up to 4 hours at room temperature (not exceeding 25°C) during administration.
- Expiry date: Do not use Paklitaxel albumin Reddy after the expiry date printed on the carton and vial (EXP). The expiry date refers to the last day of the stated month.
- Keep out of reach of children. Despite being a hospital-only medicine, any residual vials must be stored securely out of reach of children until proper disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local regulations for cytotoxic drugs. Cytotoxic waste typically requires collection in dedicated containers and incineration at licensed facilities. Your hospital pharmacy and environmental services team are responsible for proper disposal; medicines should never be disposed of via wastewater or household waste.
What Does Paklitaxel albumin Reddy Contain?
Understanding what Paklitaxel albumin Reddy contains is important for identifying potential allergens and for understanding how the formulation differs from conventional solvent-based paclitaxel.
Active Substance
- Paclitaxel: Each vial contains 100 mg of paclitaxel formulated as albumin-bound nanoparticles (nab-paclitaxel).
- After reconstitution: Each millilitre of the reconstituted suspension contains 5 mg of paclitaxel as albumin-bound nanoparticles.
Excipients (Inactive Ingredients)
- Human albumin solution: Used as the nanoparticle carrier and as the sole excipient. It contains sodium caprylate and N-acetyl-L-tryptophan as stabilizers, which are standard components of pharmaceutical-grade human albumin preparations.
- No other solvents or excipients: Paklitaxel albumin Reddy does not contain Cremophor EL, ethanol, polysorbate 80, or any other organic solvent that could trigger hypersensitivity reactions.
Appearance: Paklitaxel albumin Reddy is a white to yellowish lyophilized (freeze-dried) powder supplied in a single-use glass vial. After reconstitution with 20 ml of sodium chloride 0.9% solution, the suspension appears milky and homogeneous without visible precipitates or foreign particles. Some settling of the reconstituted suspension may occur and is considered normal; the vial should be gently inverted to resuspend before withdrawing the calculated dose.
Pack size: Each carton contains one glass vial of 100 mg paclitaxel as albumin-bound nanoparticles.
Marketing authorization holder: Dr. Reddy's Laboratories (or its relevant European or international subsidiary, depending on jurisdiction). Consult the package leaflet of the product you receive for the exact authorization holder and local representative.
Related Products Containing the Same Active Substance
Paclitaxel albumin-bound nanoparticles (nab-paclitaxel) are marketed under several brand and generic names worldwide. Besides Paklitaxel albumin Reddy, commercially available versions include Abraxane (originator product), Pazenir, Pacligen, Paclitaxel Fresenius Kabi, Paclitaxel Accord, Apexelsin, and NAVERUCLIF. While the active substance and nanoparticle formulation are considered equivalent across these products, always follow the specific prescribing information for the product you actually receive, and inform your oncology team if you are switched between brands during a treatment course.
Frequently Asked Questions About Paklitaxel albumin Reddy
Paklitaxel albumin Reddy is a generic version of the reference product Abraxane. Both medicines contain the same active ingredient: paclitaxel bound to human serum albumin as nanoparticles approximately 130 nanometers in diameter. Both are supplied as a lyophilized powder that is reconstituted to a milky suspension at 5 mg/ml and administered as a 30-minute intravenous infusion. The clinical indications, dosing, and expected efficacy and safety profile are considered equivalent. The main differences between Paklitaxel albumin Reddy and Abraxane relate to the manufacturer, packaging, and pricing; Paklitaxel albumin Reddy is produced by Dr. Reddy's Laboratories.
The key difference lies in the formulation and delivery system. Conventional paclitaxel (Taxol and its generics) uses the solvent Cremophor EL (polyoxyethylated castor oil) to dissolve the drug, which can cause severe allergic reactions and requires extensive premedication with corticosteroids and antihistamines as well as 3-hour infusion times. Paklitaxel albumin Reddy, like other nab-paclitaxel products, uses albumin nanoparticle technology instead. This eliminates the need for toxic solvents, allows shorter 30-minute infusions without routine premedication, and may help deliver more drug directly to tumors through albumin receptor-mediated transport (gp60 / SPARC pathway).
Yes. Hair loss (alopecia) is one of the most common side effects of Paklitaxel albumin Reddy, occurring in the majority of patients. It typically begins within the first month of treatment and is often pronounced, with more than 50% scalp hair loss in most affected patients; eyelashes and eyebrows may also thin. Hair loss is almost always temporary, and hair usually begins to regrow within a few months after treatment is completed, although the texture or color of the new hair may initially differ. Scalp cooling (cold cap therapy) may help reduce the severity of hair loss in some patients; discuss this option with your oncology team before starting treatment.
Paklitaxel albumin Reddy may cause tiredness, dizziness, blurred vision, or peripheral neuropathy that can impair your ability to drive safely. If you experience any of these side effects, you should not drive, use tools, or operate machinery until the symptoms have resolved. Each patient is affected differently, so discuss your individual situation with your doctor. On days when you receive infusions, it is generally advisable to arrange for someone else to drive you home and to plan for rest.
Unlike conventional paclitaxel, Paklitaxel albumin Reddy does not routinely require premedication with corticosteroids or antihistamines. This is a significant advantage of the albumin-bound formulation, which avoids the Cremophor EL solvent that causes most hypersensitivity reactions with solvent-based paclitaxel. However, if you have previously experienced a hypersensitivity reaction to nab-paclitaxel, your oncologist may recommend premedication before subsequent infusions. Anti-emetic (anti-nausea) medication may be given separately to help prevent or manage nausea and vomiting, which is a common side effect of cytotoxic chemotherapy.
The duration of treatment varies depending on the cancer type, how well you respond to therapy, and how well you tolerate the side effects. Treatment typically continues until the cancer progresses, side effects become too severe to continue, or a defined number of cycles has been reached according to your treatment plan. For breast cancer, cycles are given every 3 weeks; for pancreatic and lung cancer, treatment follows weekly schedules within 3–4 week cycles. Some patients may receive treatment for several months. Your oncologist will regularly assess your response using imaging studies (CT, MRI, or PET scans), tumor markers, and blood tests to determine how long treatment should continue.
Numbness, tingling, or pain in the hands and feet (peripheral neuropathy) is a common side effect of Paklitaxel albumin Reddy caused by its effect on peripheral nerves. You should report these symptoms to your oncology team as soon as they appear. Your doctor will assess the severity using a standardized grading scale and may delay your next treatment, reduce your dose, or in some cases discontinue the medicine to prevent the neuropathy from worsening or becoming permanent. Mild neuropathy often improves after treatment ends, but severe neuropathy may take months to improve and can sometimes be permanent. Avoiding tight shoes, protecting your hands from extreme temperatures, gentle daily exercise, and physiotherapy may help manage symptoms.
In certain cancer types – particularly PD-L1–positive triple-negative breast cancer and some non-small cell lung cancer subtypes – nab-paclitaxel has been investigated and approved in combination with immune checkpoint inhibitors such as atezolizumab or pembrolizumab. The approval status of these combinations varies by region and indication. If you are considering combination immunotherapy, your oncologist will determine whether you are a candidate based on your tumor's biomarker profile (e.g., PD-L1 expression), your overall health, and the regulatory status in your country. Paklitaxel albumin Reddy is generally interchangeable with the reference nab-paclitaxel in approved combinations, subject to local prescribing information.
References
- European Medicines Agency (EMA). Nab-paclitaxel – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: ema.europa.eu/en/medicines
- U.S. Food and Drug Administration (FDA). Paclitaxel (protein-bound particles for injectable suspension) – Prescribing Information. Last updated 2024. Available at: fda.gov/drugs
- Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology. 2005;23(31):7794-7803. doi:10.1200/JCO.2005.04.937
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine. 2013;369(18):1691-1703. doi:10.1056/NEJMoa1304369
- Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. Journal of Clinical Oncology. 2012;30(17):2055-2062. doi:10.1200/JCO.2011.39.5848
- Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clinical Cancer Research. 2006;12(4):1317-1324. doi:10.1158/1078-0432.CCR-05-1634
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer. Version 2025. Available at: nccn.org/guidelines
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Metastatic Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer. 2024-2025. Available at: esmo.org/guidelines
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization. Paclitaxel included as an essential cancer medicine.
- Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology. 1995;13(1):180-190. doi:10.1200/JCO.1995.13.1.180
- British National Formulary (BNF). Paclitaxel. London: Joint Formulary Committee. Available at: bnf.nice.org.uk/drugs/paclitaxel
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Oncology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, and FDA guidelines
Evidence Level
Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials
Last Reviewed
– Updated according to current EMA SmPC and FDA prescribing information
All medical content on iMedic is written and reviewed by qualified healthcare professionals following the GRADE evidence framework. We adhere to strict editorial standards with no commercial funding or pharmaceutical sponsorship. For questions or corrections, please contact our editorial team.